Yahoo
NasdaqGS - Nasdaq Real Time Price USD

Integra LifeSciences Holdings Corporation (IART)

14.49 -0.33 (-2.23%)
As of 10:06:47 AM EST. Market Open.
Trade IART on Coinbase

Key Executives

Amounts are as of December 31, 2025 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.
Name Title Pay Exercised Year Born
Dr. Stuart M. Essig Ph.D.
CEO, President & Chairman 85k -- 1962
Ms. Lea Daniels Knight
Executive VP & CFO 884.7k -- 1972
Mr. Robert T. Davis Jr.
Executive Vice President of Tissue Reconstruction and Distributed Technologies 722.35k -- 1959
Mr. Michael J. McBreen
Executive VP & Chief Commercial Officer 942.93k -- 1966
Mr. Harvinder Pal Singh
Executive VP & President of International Business 714.61k -- 1966
Mr. Jeffrey A. Mosebrook
Senior VP of Finance & Principal Accounting Officer 493.14k -- 1976
Mr. Teshtar Elavia
Corporate VP & Chief Technology Officer -- -- --
Christopher Ward
Senior Director of Investor Relations -- -- --
Mr. Michael D. Hutchinson
Executive VP, Chief Legal Officer & Secretary -- -- 1971
Laurene Isip
Vice President of Global Corporate Communications & Public Relations -- -- --

Integra LifeSciences Holdings Corporation

1100 Campus Road
Princeton, NJ 08540
United States
609 275 0500 https://www.integralife.com
Sector: 
Healthcare
Industry: 
Medical Devices
Full Time Employees: 
4,427

Description

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical, ear, nose, throat, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates through Codman Specialty Surgical and Tissue Technologies segments. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment. It also offers after-market services; surgical headlamps and instrumentation; instrument patterns and surgical and lighting products to hospitals, surgery centers, dental, podiatry, and veterinary offices. In addition, the company provides treatment of acute wounds, such as burns; chronic wounds, including diabetic foot ulcers; and surgical tissue repair applications, including hernia reinforcement, tendon protection, and peripheral nerve repair. Further, it offers skin and wound repair, plastics and surgical reconstruction products, and nerve and tendon repair products. Additionally, the company is involved in the ear, nose, and throat business that includes instrumentation, balloon technologies for sinus dilation and eustachian tube dilation, and surgical navigation systems. It offers its products directly through various salesforces and other distribution channels to the hospitals, integrated health networks, group purchasing organizations, clinicians, surgery centers, and health care providers in the United States, Europe, the Asia Pacific, and internationally. Integra LifeSciences Holdings Corporation was formerly known as Integra LifeSciences Corp. and changed its name to Integra LifeSciences Holdings Corporation in June 1995. Integra LifeSciences Holdings Corporation was incorporated in 1989 and is headquartered in Princeton, New Jersey.

Corporate Governance

Integra LifeSciences Holdings Corporation’s ISS Governance QualityScore as of November 1, 2026 is 2. The pillar scores are Audit: 1; Board: 3; Shareholder Rights: 1; Compensation: 5.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.

Upcoming Events

October 21, 2026 at 12:30 PM UTC

Integra LifeSciences Holdings Corporation Earnings Date

Recent Events

October 23, 2026 at 12:00 AM UTC

10-Q: Periodic Financial Reports

October 21, 2026 at 12:00 AM UTC

8-K: Corporate Changes & Voting Matters

October 19, 2026 at 12:00 AM UTC

8-K: Corporate Changes & Voting Matters

October 9, 2026 at 12:00 AM UTC

8-K: Corporate Changes & Voting Matters

October 2, 2026 at 12:00 AM UTC

8-K: Corporate Changes & Voting Matters

September 8, 2026 at 12:00 AM UTC

8-K: Corporate Changes & Voting Matters

July 29, 2026 at 12:00 AM UTC

10-Q: Periodic Financial Reports

May 29, 2026 at 12:00 AM UTC

SD: Specialized Disclosure Report filed pursuant to Section 1502 of the Dodd-Frank Wall Street Reform and Consumer Protection Act relating to the use of conflict minerals (Rule 13p-1)

May 8, 2026 at 12:00 AM UTC

8-K: Corporate Changes & Voting Matters

May 5, 2026 at 12:00 AM UTC

10-Q: Periodic Financial Reports

Related Tickers

Mobilize your Website
View Site in Mobile | Classic
Share by: